Publications by Fredrik Hellem Schjesvold

30 publications found

Publications 2021

  1. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2021)
    Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
    Ann Hematol, 100 (1), 297-302
    DOI 10.1007/s00277-020-04302-0, PubMed 33106909

Publications 2020

  1. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2020)
    Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
    Ann Hematol, 99 (8), 1793-1804
    DOI 10.1007/s00277-020-04149-5, PubMed 32613281
  2. Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S (2020)
    Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
    Am J Hematol (in press)
    DOI 10.1002/ajh.26083, PubMed 33368455
  3. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF et al. (2020)
    Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
    Lancet Oncol, 22 (1), 142-154
    DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738
  4. Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodríguez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG (2020)
    Melflufen for relapsed and refractory multiple myeloma
    Expert Opin Investig Drugs, 29 (10), 1069-1078
    DOI 10.1080/13543784.2020.1808884, PubMed 32924646
  5. Schjesvold F (2020)
    Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
    Eur J Haematol, 105 (4), 434-448
    DOI 10.1111/ejh.13464, PubMed 32557833
  6. Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M (2020)
    Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
    Eur J Haematol, 104 (5), 443-458
    DOI 10.1111/ejh.13379, PubMed 31880006
  7. Schjesvold F, Robak P, Pour L, Aschan J, Sonneveld P (2020)
    OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
    Future Oncol, 16 (11), 631-641
    DOI 10.2217/fon-2020-0024, PubMed 32141766
  8. Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S (2020)
    Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Haematologica (in press)
    DOI 10.3324/haematol.2020.253450, PubMed 32586908
  9. Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B et al. (2020)
    Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
    Haematologica, 105 (12), 2879-2882
    DOI 10.3324/haematol.2019.240374, PubMed 33256392

Publications 2019

  1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
    Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Lancet, 394 (10214), 2096-2107
    DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560
  2. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H et al. (2019)
    International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
    Lancet Oncol, 20 (6), e302-e312
    DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104
  3. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P et al. (2019)
    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
    Lancet Haematol, 6 (9), e459-e469
    DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687
  4. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M et al. (2019)
    Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Lancet Oncol, 20 (6), 781-794
    DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405
  5. Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators (2019)
    Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
    Lancet Haematol, 6 (9), e448-e458
    DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689

Publications 2018

  1. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R et al. (2018)
    Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
    Lancet, 393 (10168), 253-264
    DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780
  2. Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
    Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
    BMC Cancer, 18 (1), 801
    DOI 10.1186/s12885-018-4722-x, PubMed 30089450
  3. Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
    In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
    Blood, 132, 4676
    DOI 10.1182/blood-2018-99-110357, PublikaID 304
  4. Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
    Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
    Blood, 132, 4677
    DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2017

  1. Schjesvold FH (2017)
    Immunologiske mekanismer for drap av kreftceller
    Tidsskr Nor Laegeforen, 137 (1), 58
    DOI 10.4045/tidsskr.16.0963, PubMed 28073239
  2. Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
    Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
    Leukemia, 31 (10), 2114-2121
    DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

  1. Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
    Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
    Clin Microbiol Infect, 23 (3), 179-187
    DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

  1. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
    Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
    Cancer Res, 75 (16), 3268-78
    DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

  1. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
    How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
    Front Immunol, 5, 174
    DOI 10.3389/fimmu.2014.00174, PubMed 24782871
  2. Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
    Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
    Eur J Immunol, 44 (9), 2625-37
    DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

  1. Schjesvold F, Wiencke K, Tjønnfjord GE (2013)
    [Investigation of anemia]
    Tidsskr Nor Laegeforen, 133 (6), 610
    DOI 10.4045/tidsskr.13.0256, PubMed 23552139
  2. Schjesvold FH (2013)
    [Investigation of amyloidosis]
    Tidsskr Nor Laegeforen, 133 (3), 266
    DOI 10.4045/tidsskr.13.0044, PubMed 23381155

Publications 2012

  1. Tazmini K, Bakken HN, Schjesvold FH (2012)
    A woman in her seventies with reduced general condition, dyspnoea and generalised pain
    Tidsskr Nor Laegeforen, 132 (17), 1969-72
    DOI 10.4045/tidsskr.11.0608, PubMed 23007363

Publications 2009

  1. Schjesvold FH (2009)
    [Erythrocytosis as a problem]
    Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
    DOI 10.4045/tidsskr.09.1196, PubMed 19935946

Publications 2008

  1. Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
    [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
    Tidsskr Nor Laegeforen, 128 (12), 1392-6
    PubMed 18552900
 
Page visits: 3069